FDA Approves Inluriyo In Combination With Verzenio For ER+, HER2-, ESR1-Mutated Advanced Breast Cancer
LLY•FDA approves Inluriyo combination treatment
Sept. 18 (Reuters) - Eli Lilly and Company LLY.N:
- U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.
- Eli Lilly said Inluriyo with Verzenio is now available in the United States.
